The document “Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001” was lodged with ASX on 25 November 2020. Please click to review the
Imagion Biosystems announces that it has received a total of $644,100.00 for the exercise of Options. Please click to review the full announcement at ASX.
Imagion Biosystems Limited announced a proposed issue of securities on 22 November 2020. Please click to review the full announcement at ASX.
Imagion Biosystems is pleased to announce it has raised $6M via a placement, at 8.5c per share. The placement, led by Evolution Capital Advisors, was
The securities of Imagion Biosystems Limited (‘IBX’) will be placed in trading halt at the request of IBX, pending it releasing an announcement. Unless ASX
Imagion Biosystems advises that in accordance with Listing Rule 4.7C.3, and as noted in the Item 6 of the Appendix 4C Cashflow Statement lodged by
Imagion Biosystems has released their Quarterly Activity Report for the period ended 30 September 2020 and Appendix C. Q3 Highlights Raised $4.7M (after costs) in
Imagion Biosystems gave ASX information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Imagion Biosystems has submitted “Appendix 2A — Application for quotation of +securities.” Read Appendix 2A.
Imagion Biosystems has advised that 2,500,000 performance rights have vested and were issued as ordinary shares to Executive Chairman and CEO Bob Proulx today, Thursday